Sector News

Celgene’s R&D report card ‘somewhat disappointing,' say analysts

May 28, 2018
Life sciences

An audit of Celgene’s R&D over the last five years has revealed that two-thirds of its programs failed—and it made no difference whether the project originated in-house or externally.

The analysis by analysts at Leerink looked at Celgene’s R&D presentations in 2013 and 2014 and found that only one out of 20 programs has resulted in a marketed product, namely Otezla (apremilast) for psoriasis. Furthermore, 14 out of 28 projects have disappeared from the portfolio in the last two years.

“This turnover raises questions about how much value to give to those programs still in development, and is consistent with our prior analysis suggesting that Celgene’s stock is discounting little or no value for its non-phase 3 pipeline,” the analysts wrote in a research note.

The company’s relatively weak stock value of late—pegged back by R&D setbacks such as a big delay for multiple sclerosis candidate ozanimod and an over-reliance on multiple myeloma drug Revlimid (lenalidomide)—suggests that investors have assigned very little value to its pipeline. Leerink said the productivity of Celgene’s R&D activity in the past five years “suggests the current negative sentiment may be warranted.”

Celgene’s R&D strategy over the last few years has been to forge partnerships for early-stage programs while acquiring companies with promising later-stage drugs. The latter approach yielded acute myeloid leukemia Idhifa (enasidenib), which other than Otezla is Celgene’s only other launch in the last five years.

Overall, the company’s much-trumpeted strategy doesn’t seem to give a higher success rate in R&D than its peers, said the analysts.

“Celgene’s unique convention-defying strategy and structure have not necessarily yielded more new chemical entities (NCEs) or better success rates than more traditional (focused) approaches to product discovery and development,” they suggested.

While there still seems to be plenty of scope for growth with Revlimid—Leerink is estimating sales will rise from a little over $8 billion last year to $14.78 billion in 2022—the company has a lot of work to do to prepare for possible generic competition to its cash cow drug at the end of that forecast period.

“Celgene is invested in rights to a broad array of novel technologies and products in hematology, oncology, and inflammatory diseases,” Leerink said.

“The potential of these products remains to be seen, but 2018 is shaping up to be a critical year for assessing the value, and likely return, from these investments.”

By Phil Taylor

Source: Fierce Biotech

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.